New molecular targets in pancreatic cancer;Nouvelles cibles moléculaires dans le cancer du pancréas

Bulletin du Cancer

Volumn 95, Issue 5, 2008, Pages 503-512

  Torrisani, Jérôme ^a   Bournet, Barbara ^a   Cordelier, Pierre ^a   Buscail, Louis ^a  

^a INSERM   (France)

Author keywords

Chemoresistance; EGF receptor; Epigenetic modification; K ras oncogene; MicroRNA; Pancreatic carcinoma

Indexed keywords

BETA INTEGRIN; BOMBESIN; BOMBESIN RECEPTOR; ENDOTHELIAL CELL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; GASTRIN; GASTRIN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METALLOPROTEINASE; METHYLTRANSFERASE INHIBITOR; MICRORNA; MOLECULAR MARKER; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN P16; PROTEIN P53; SMAD4 PROTEIN; TELOMERASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UVOMORULIN; VASCULOTROPIN;

ACETYLATION; CANCER GROWTH; CANCER MODEL; CODON; DIFFERENTIAL DIAGNOSIS; ENZYME ACTIVITY; EPIGENETICS; GENE ACTIVATION; GENE INACTIVATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; METHYLATION; ONCOGENE K RAS; PANCREAS CANCER; PANCREAS CARCINOMA; PROTEIN EXPRESSION; REVIEW;

ANGIOGENIC PROTEINS; ANIMALS; GENES, P16; GENES, P53; GENES, RAS; GENES, TUMOR SUPPRESSOR; GROWTH SUBSTANCES; HUMANS; MICE; NF-KAPPA B; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; SMAD4 PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 45949086258     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0632     Document Type: Review

References (34)

1. Warshaw AL, Fernandez-del-Castillo C. Pancreatic carcinoma. N Engl J Med 1992 ; 326 : 455-65.
2. Buscail L, Pagès P, Berthelémy P, Fourtanier F, Frexinos J, Escourrou J. Role of EUS in the management of pancrearic and ampullary carcinoma : a prospective study assessing resectability and prognosis. Gastrointest Endosc 1999 ; 50 : 34-40.
3. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 1997 ; 15 : 2403-13.
4. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma : a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002 ; 94 : 902-10.
5. Blanchard P, Huguet F, André T. Gemcitabine and digestive carcinomas. Bull Cancer 2007 ; 94 : S104-SH5.
6. Benali N, Cordelier P, Calise D, Pagès P, Rochaix P, Nagy A, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster following sst2 receptor gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci USA 2000 ; 97 : 9180-5.
7. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, et al. Tumor induction by an endogenous K-ras oncogene is highly dependenr on cellular context. Cancer Cell 2003 ; 4 : 111-20.
8. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia : evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000 ; 60 : 2002-6.
9. Torrisani J, Buscail L. Molecular pathways of pancreatic carcinogenesis. Ann Pathol 2002 ; 22 : 349-55.
10. Hilgers W, Rosty C, Hahn SA. Molecular pathogenesis of pancreatic cancer. Hematol Oncol Clin North Am 2002 ; 16 : 17-35.
11. Delesque N, Buscail L, Estève JP, Saint-Laurent N, Müller C, Weckbecker G, et al. sst2 somatostatin receptor expression reverses the tumorigenicity of human pancreatic cancer cells. Cancer Res 1997 ; 57 : 956-62.
12. Berthelémy P, Bouisson M, Escourrou J, Vaysse N, Rumeau JL, Pradayrol L. Identification of K-ras mutation in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995 ; 123 : 188-91.
13. Bournet B, Souque A, Senesse P, Barthet M, Lesavre N, O'Toole D, et al. Performances diagnostiques de la recherche de la mutation de l'oncogène k-ras couplée à la ponction-biopsie sous échoendoscopie pour le diagnostic des masses solides pancréatiques : étude prospective multicentrique incluant 119 patients. Gastroenterol Clin Biol 2007 ; 31 : A225.
14. Marchese R, Muleti A, Pasqualetti P, Bucci B, Stigliano A, Brunetti E, et al. S. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas 2006 ; 32 : 171-7.
15. Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007 ; 109 : 1561-9.
16. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 2006 ; 5 : 1387-95.
17. Costentin L, Bouisson M, Pagès P, Buscail L, Berthelèmy P, Escourrou J, et al. Deletions of p16/MTS-1 and DPC-4 gene is frequent event in pancreatic juice from patients with pancreatic cancer and chronic pancreatitis. Pancreatol 2002 ; 2 : 17-25.
18. Carrere N, Vernejoul F, Souque A, Asnacios A, Vaysse N, Pradayrol L, et al. Characterization of the bystander effect of somatostatin receptor sst2 after in vivo gene transfer into human pancreatic cancer cells. Hum Gene Ther 2005 ; 16 : 1175-93.
19. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, et al. Funcrion of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 2003 ; 9 : 346-54.
20. Lee SH, Ryu JK, Lee KY, Woo SM, Park JK, Yoo JW, et al. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett 2008 ; 259 : 39-49.
21. Rosty C. Towards the identification of new markers of pancreatic cancer by gene expression analysis. Bull Cancer 2004 ; 91 : 593-8.
22. Mathelin C, Tomasetto C, Rio MC. Trefoil factor 1 (pS2/TFF1), a peptide with numerous functions. Bull Cancer 2005 ; 92 : 773-81.
23. Laurell H, Bouisson M, Berthelemy P, Rochaix P, Dejean S, Besse P, et al. Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J Gastroenterol 2006 ; 12 : 3344-51.
24. Buchholz M, Braun M, Heidenblut A, Kestler HA, Klöppel G, Schmiegel W, et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 2005 ; 24 : 6626-36.
25. Chen R, Brentnall TA, Pan S, Cooke K, Moyes KW, et al. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics 2007 ; 6 : 1331-42.
26. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 ; 25 : 1960-6.
27. Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, et al. Usefulness of predictive tests for cancer treatment. Bull Cancer 2006 ; 93 : E101-E108.
28. Di Flore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007 ; 96 : 1166-9.
29. Larbouret C, Robert B, Teulon I, Assénat E, Azria D, Pèlegrin A. Combination of anti-EGFR and anti-HER2 antibodies : hope in pancreatic cancer treatment. Bull Cancer 2007 ; 94 : 860-2.
30. Szyf M. Targeting DNA methylation in cancer. Bull Cancer 2006 ; 93 : 961-72.
31. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007 ; 26 : 4442-52.
32. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007 ; 120 : 1046-54.
33. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006 ; 66 : 3928-35.
34. Vernejoul F, Ghenassia L, Souque A, Lulka H, Drocourt D, Cordelier P, et al. Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol Ther 2006 ; 14 : 758-67.